Coordination modes of bidentate lornoxicam drug with some transition metal ions. Synthesis, characterization and in vitro antimicrobial and antibreastic cancer activity studies

• Mononuclear complexes of lornoxicam drug with transition metal ions were prepared.
• The bonding and stereochemistry were deduced from elemental and spectroscopic data.
• The activation kinetic parameters are calculated using DTG curves.
• The metal complexes showed antimicrobial inhibition capacity comparable to LOR ligand.
• The Cr(III), Fe(II) and Cu(II) complexes have high anticancer activity against MCF7.

The NSAID lornoxicam (LOR) drug was used for complex formation reactions with different metal salts like Cr(III), Mn(II), Fe(III) and Ni(II) chlorides and Fe(II), Co(II), Cu(II) and Zn(II) borates. Mononuclear complexes of these metals are obtained that coordinated to NO sites of LOR ligand molecule. The nature of bonding and the stereochemistry of the complexes have been deduced from elemental analyses, IR, UV–Vis, 1H NMR, mass, electronic spectra, magnetic susceptibility and ESR spectral studies, conductivity measurements, thermogravimetric analyses (TG–DTG) and further confirmed by X-ray powder diffraction. The activation thermodynamic parameters are calculated using Coats–Redfern and Horowitz–Metzger methods. The data show that the complexes have composition of ML2 type except for Fe(II) where the type is [ML3]. The electronic absorption spectral data of the complexes suggest an octahedral geometry around the central metal ion for all the complexes. The antimicrobial data reveals that LOR ligand in solution show inhibition capacity less or sometimes more than the corresponding complexes against all the species under study. In order to establish their future potential in biomedical applications, anticancer evaluation studies against standard breast cancer cell lines (MCF7) was performed using different concentrations. The obtained results indicate high inhibition activity for Cr(III), Fe(II) and Cu(II) complexes against breast cancer cell line (MCF7) and recommends them for testing as antitumor agents.

MCo(II), Cu(II) and Zn(II) complexes MCr(III), Mn(II), Fe(III) and Ni(II) complexes.Figure optionsDownload as PowerPoint slide